Bristol Myers Squibb (CELG-RI) Non-Current Deferred Tax Liability (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 15 years of Non-Current Deferred Tax Liability data on file, last reported at $211.0 million in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $211.0 million, down 23.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $211.0 million (down 23.55% YoY), and the FY2025 annual result was $222.0 million, down 95.14% from the prior year.
• Non-Current Deferred Tax Liability retreated to $211.0 million in Q1 2026 per CELG-RI's latest filing, from $222.0 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $4.9 billion in Q4 2023 and troughed at $211.0 million in Q1 2026.
• A 5-year average of $1.6 billion and a median of $461.0 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deferred Tax Liability surged 126.41% in 2023, then sank 95.14% in 2025.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.2 billion in 2022, then jumped by 126.41% to $4.9 billion in 2023, then decreased by 6.77% to $4.6 billion in 2024, then slumped by 95.14% to $222.0 million in 2025, then retreated by 4.95% to $211.0 million in 2026.
• Business Quant data shows CELG-RI's Non-Current Deferred Tax Liability at $211.0 million in Q1 2026, $222.0 million in Q4 2025, and $225.0 million in Q3 2025.